Rchr
J-GLOBAL ID:201401096136196702   Update date: Feb. 01, 2024

Tada Harue

Tada Harue
Affiliation and department:
Research field  (1): Medical equipment testing
Research theme for competitive and other funds  (3):
  • 2009 - 2013 Association of geomagnetic disturbances and suicides
  • 2008 - 2010 Development of device using color images to reduce stress in cancer and/or other chronic disease patients.
  • 2006 - 2007 ストレス緩和のための色彩映像媒体の開発
Papers (66):
  • Hiroki Yamanaka, Eiichi Sawaragi, Takashi Nakano, Yasuhiro Katayama, Tatsuya Ito, Harue Tada, Yu Hidaka, Satoshi Morita, Chihiro Funakoshi, Akemi Kinoshita, et al. A high-hydrostatic pressure device for nevus tissue inactivation and dermal regeneration for reconstructing skin defects after giant congenital melanocytic nevus excision: a clinical trial. Regenerative Therapy. 2023. 24. 167-173
  • Naoshi Sugimoto, Junya Kanda, Sou Nakamura, Toshiyuki Kitano, Masakatsu Hishizawa, Tadakazu Kondo, Shin Shimizu, Akiko Shigemasa, Hideyo Hirai, Yasuyuki Arai, et al. iPLAT1: The first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study. Blood. 2022. 140. 22. 2398-2402
  • Shusuke Akamatsu, Naoki Terada, Ryo Takata, Hidefumi Kinoshita, Kimihiro Shimatani, Yukihide Momozawa, Michio Yamamoto, Harue Tada, Naoki Kawamorita, Shintaro Narita, et al. Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy. JNCI cancer spectrum. 2022. 6. 1
  • Yukiko Mori, Osamu Kikuchi, Takahiro Horimatsu, Hiroki Hara, Shuichi Hironaka, Takashi Kojima, Ken Kato, Takahiro Tsushima, Ryu Ishihara, Kumi Mukai, et al. Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study. Esophagus : official journal of the Japan Esophageal Society. 2022. 19. 3. 444-451
  • Takashi Nomura, Eriko Sumi, Gyohei Egawa, Saeko Nakajima, Eiko Toichi, Nana Inoue, Mami Shibuya, Natsuko Okamoto, Tsuyoshi Mitsuishi, Ryuji Uozumi, et al. Safety and Efficacy of FIT039 for Verruca Vulgaris: A Placebo-Controlled, Phase I/II Randomized Controlled Trial. JID innovations : skin science from molecules to population health. 2021. 1. 3. 100026-100026
more...
MISC (114):
more...
Patents (3):
Lectures and oral presentations  (9):
  • 臨床試験における品質マネジメントシステム
    (社会健康医学・臨床疫学研究コース 2023)
  • 再生医療におけるプロトコール
    (iPS再生医療各論 2023)
  • 臨床試験に携わる人々
    (高度医療看護論 2023)
  • 先進医療制度と臨床試験
    (高度医療看護論 2023)
  • REDCap:自分で作るEDC
    (臨床研究推進セミナー特別回 2023)
more...
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page